Bide Pharmatech (SH:688073)2023-10-27 16:00Financial Performance - The company's operating revenue for Q3 2023 was ¥282,381,419.24, representing a year-on-year increase of 28.44%[5] - The net profit attributable to shareholders for Q3 2023 was ¥29,588,307.31, a decrease of 23.83% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥29,142,908.49, down 21.48% year-on-year[5] - Total operating revenue for the first three quarters of 2023 reached ¥805,006,735.83, a 36.8% increase from ¥588,523,507.84 in the same period of 2022[21] - Net profit for the third quarter of 2023 was ¥112,647,629.62, compared to ¥98,019,929.93 in the previous year, indicating a growth of 14.5%[24] - Basic earnings per share for the third quarter increased to ¥1.25 from ¥1.08, representing a 15.7% rise[25] Research and Development - The total R&D investment for Q3 2023 was ¥14,367,504.10, an increase of 0.86% compared to the same period last year[6] - The R&D investment accounted for 5.09% of operating revenue, a decrease of 1.39 percentage points year-on-year[6] - Research and development expenses for the first three quarters were ¥41,143,681.30, up from ¥32,707,671.39, indicating a 25.7% increase in investment in innovation[23] Assets and Liabilities - The total assets at the end of Q3 2023 were ¥2,414,261,322.99, reflecting a 2.33% increase from the end of the previous year[6] - Total assets as of September 30, 2023, amounted to CNY 2,414,261,322.99, an increase from CNY 2,359,206,247.92 at the end of 2022[16] - Total liabilities as of September 30, 2023, were CNY 278,664,145.19, compared to CNY 249,070,839.56 in the previous year[18] - Total liabilities increased to ¥331,918,644.15 from ¥283,052,077.86, reflecting a growth of 17.3%[23] - The equity attributable to shareholders at the end of Q3 2023 was ¥2,083,093,735.68, a slight increase of 0.33% compared to the end of the previous year[6] - Total equity attributable to shareholders rose to ¥2,083,093,735.68 from ¥2,076,154,170.06, a slight increase of 0.3%[23] Cash Flow - The company reported a cash flow from operating activities of ¥122,873,122.85 for the year-to-date period[6] - Cash flow from operating activities for the first three quarters was ¥841,311,762.23, compared to ¥635,367,173.58 in the same period last year, showing a 32.4% increase[28] - Cash outflow from operating activities totaled approximately $964.18 million, compared to $639.40 million in the previous year, indicating a year-over-year increase of 50.7%[29] - The net cash flow from operating activities was negative at approximately -$122.87 million, worsening from -$4.03 million in the same quarter last year[29] - The company reported a cash outflow of approximately $100.03 million for dividend distributions and interest payments, compared to $45.49 million in the previous year[30] Shareholder Information - The company’s major shareholders include Dai Lan and Dai Long, who collectively hold 46.90% of the shares[14] - The top ten shareholders hold a significant portion of the company’s equity, with the largest shareholder holding 32.4%[13] Future Outlook - Future outlook includes potential market expansion and strategic acquisitions to enhance growth[15] - The company has ongoing investments in new technologies and product development, although specific figures were not disclosed in the report[15] Accounting Changes - The company has adopted new accounting standards starting in 2023, which may affect the financial statements[31]